Results 101 to 110 of about 3,601 (174)

Comparative effects of oxaliplatin-based versus irinotecan-based regimens combined with capecitabine and bevacizumab in patients with colorectal cancer and liver metastases. [PDF]

Am J Cancer Res
Liang Y, Lei M, Zhang B.
europepmc   +1 more source

Thapsigargin enhanced chemotherapeutic sensitivity of irinotecan in the inflammation-induced colorectal cancer model in mice. [PDF]

Sci Rep
Baruah S, Bharali MK, Akhtara N, Nath JK, Rahman SS, Rasid SS, Baidya M, Khan EMMS, Mishra R.   +8 more
europepmc   +1 more source

Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. [PDF]

BMC Cancer
Decraecker M, Le Joncour S, Aurillac V, Sangnier M, Ducerf C, Berroneau A, Rouleau L, Tougeron D, Laplace C, Madau M, Dumon C, Perrier H, Blanc JF.   +12 more
europepmc   +1 more source

Decoding cross-talk between Mpox and HIV: insights from transcriptomics and network-based analyses. [PDF]

Virol J
Mishra SK, Chhetri T, Roy S, Al-Mutairi AA, Aragaw AA, Sindi ER, Zaki MEA, Georrge JJ.   +7 more
europepmc   +1 more source

Autophagy and PXR Crosstalk in the Regulation of Cancer Drug Metabolism and Resistance According to Gene Mutational Status in Colorectal Cancer. [PDF]

Genes (Basel)
Koustas E, Sarantis P, Trifylli EM, Dikoglou-Tzanetatou E, Ioakeimidou E, Anastasiou IA, Karamouzis MV, Theocharis S.   +7 more
europepmc   +1 more source

Double Trouble: EPCAM Exon 9 Deletion in Lynch Syndrome Leading to Dual Primary Tumors. [PDF]

Cureus
Kalfoutzou A, Rapti C, Almpanis Z, Bagiokou E, Kalakos N, Lagopoulou V, Kolintzikis V, Oikonomakis A, Chaleplidis N, Ramfidis V.   +9 more
europepmc   +1 more source

Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants. [PDF]

Int J Mol Sci
Mostaq MS, Amin MN, Raphael A, Asbury C, Gupta A, Gu X, Han X, Sekulic D, Michalak P, Kang L, Liu YY.   +10 more
europepmc   +1 more source

Engineered tumor-tropic mesenchymal stem cells as targeted therapeutic delivery systems for refractory Ovarian cancer. [PDF]

J Control Release
Li G, Massumi M, Owji H, Yang G, Girda E, Hatefi A.   +5 more
europepmc   +1 more source

CAMPTO® (irinotecan hydrochloride)

Japanese Journal of National Medical Services, 2008
openaire   +1 more source

High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma. [PDF]

PLoS One
Tseng PJ, Sinenko IL, Chambon M, Banfi D, Zugbi S, Cancela MB, Glinkina KA, Turcatti G, Stathopoulos C, Schaiquevich P, Munier FL, Dyson PJ.   +11 more
europepmc   +1 more source